Showing results (81-90 of 342) with videos related to
Sort By:
Pageof 35
Blood Cells, Molecules & Diseases|April 2, 2003
Fluorescent flow cytometric assay: a new diagnostic tool for measuring beta-glucocerebrosidase activity in Gaucher diseaseBernard Rudensky, Esther Paz, Gheona Altarescu, et al.American Journal of Clinical Pathology|June 15, 2013
Histologic findings of femoral heads from patients with Gaucher disease treated with enzyme replacementEhud Lebel, Deborah Elstein, Ariel Peleg, et al.Advanced Drug Delivery Reviews|June 28, 2022
Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson diseaseMia Horowitz, Hila Braunstein, Ari Zimran, et al.Journal of Osteoporosis|December 16, 2014
Bone mineral density in gravida: effect of pregnancies and breast-feeding in women of differing ages and parityEhud Lebel, Yuri Mishukov, Liana Babchenko, et al.Blood Cells, Molecules & Diseases|October 14, 2015
13,845 home therapy infusions with velaglucerase alfa exemplify safety of velaglucerase alfa and increased compliance to every-other-week intravenous enzyme replacement therapy for Gaucher diseaseDeborah Elstein, Aya Abrahamov, Anat Oz, et al.Blood Cells, Molecules & Diseases|November 19, 2016
UPR activation and CHOP mediated induction of GBA1 transcription in Gaucher diseaseHila Braunstein, Gali Maor, Gaya Chicco, et al.Internal Medicine Journal|May 21, 2025
Hyperuricaemia in type 1 Gaucher disease: is uric acid a biomarker for disease severity?Zufit Hexner-Erlichman, Salmas Watad, Jeff Szer, et al.Bone Marrow Transplantation|June 16, 2018
Strategies to enhance the graft versus tumour effect after allogeneic haematopoietic stem cell transplantationEric Wong, Joanne E Davis, Andrew Grigg, et al.Internal Medicine Journal|June 28, 2022
Fat fraction quantification of bone marrow in the lumbar spine using the LiverLab assessment tool in healthy adult volunteers and patients with Gaucher diseaseCalvin Gan, Patricia L Robertson, Jeffrey K C Lai, et al.Cancer|February 22, 2002
Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphomaJohn F Seymour, Andrew P Grigg, Jeff Szer, et al.Pageof 35